VB100 MedTech Release Day Concludes Successfully, Highlighting Medical Robotics Innovation and Sterilization Supply Services
On April 16, 2019, the VB100 Medical Devices Themed Launch Day, hosted by VCBeat, concluded successfully at Lingang Pujiang Technology Plaza in Shanghai. As the first launch day dedicated to the healthcare industry in China, VB100 Launch Day is one of VCBeat’s flagship events and has been held for three consecutive years.
This launch event focused on two key segments: the inaugural Medtronic China Fund–BV Baidu Ventures Medical Robotics Competition, and the major release of the “Special Report on Third-Party Sterile Supply Centers” by VCBeat and VBInsight. Distinguished experts and scholars gathered in large numbers, while dozens of professional media outlets from the healthcare, technology, venture capital, and financial sectors were invited to attend. Through coordinated online coverage, the event served enterprises, listed companies, investment institutions, healthcare service providers, industrial parks, and government agencies with information dissemination needs, amplifying their voices and jointly witnessing the announcement of the following significant updates.
Medtronic China Fund - BV Baidu Ventures Medical Robotics Competition Officially Launches
This competition will focus on medical robots and related fields, targeting startups, teams, universities, and research institutions. It seeks innovative application solutions for medical robots in specific scenarios, promoting the integrated development of “technology + capital + talent + applications” in the medical robotics sector. By providing high-quality projects with robust incubation opportunities, industrial collaboration, and financial support, the competition aims to encourage and advance innovation in China’s medical robotics industry. Through intelligent manufacturing in China, it strives to contribute to progress in medical technology and benefit a wide range of patients.
Regarding the current state and future development trends of the medical robotics industry, Professor Zhao Xu from the Institute of Medical Robotics at Shanghai Jiao Tong University stated: “From a technical perspective, medical robotics is a highly interdisciplinary field, integrating engineering, medicine, materials science, artificial intelligence, and other disciplines. It can be categorized into surgical, rehabilitation, patient transfer, and logistics robots, covering the entire healthcare process. Given its exceptional complexity, it is not an exaggeration to refer to it as the ‘crown jewel’ of the industry. Building a robust and scalable industry requires the convergence of talent from various sectors, which presents significant challenges. Over the past few decades, global efforts in this field have intensified, which formed the backdrop for the establishment of the Institute of Medical Robotics at Shanghai Jiao Tong University. The challenges facing the medical robotics industry can be summarized in two key aspects: First, automation—currently, these systems primarily serve as assistive tools for physicians, and devices need to evolve toward intelligent diagnostics. Second, miniaturization—implantable devices must be biocompatible for safe long-term placement within the human body to achieve ultimate clinical application. Centered on precision medicine and minimally invasive techniques, these areas represent enduring opportunities and challenges.”
As an innovative leader in the global medical technology sector, Medtronic boasts nearly 70 years of experience in the healthcare industry, with operations spanning 150 countries worldwide and covering more than 70 disease areas, thereby possessing extensive expertise and unique insights into the healthcare market. Medical robotics represents a key strategic direction for Medtronic’s research and development and innovation efforts. Globally, Medtronic is actively expanding its presence in the fields of surgical and orthopedic robotic systems. In China, Medtronic has undertaken multiple local R&D initiatives in recent years focused on surgical robots and artificial intelligence, fostering the application and rapid translation of these technologies through joint university R&D projects and medical accelerator platforms.
At the event, Shi Yonghui, Managing Director of the Medtronic China Fund, stated, “China’s current medical technology landscape is a vibrant hub of innovation. The Medtronic China Fund was established to leverage Medtronic’s market insights and professional expertise in medical technology to identify and support innovative projects with significant clinical and commercial potential, thereby meeting local healthcare needs through accelerated technology translation. Medical robotics and artificial intelligence represent key directions in the advancement of medical technology. We are highly enthusiastic about co-hosting this competition with Baidu Ventures, as we look forward to discovering outstanding projects that combine technological leadership with strong potential for clinical translation.”
Biomedical technology has long been a key focus of BV Baidu Ventures’ strategic investments. From AI-driven drug discovery to next-generation surgical robots, and from single-cell sequencing to in vivo sensors, BV has visited countless laboratories across China and the United States in its two years since establishment, investing in more than 30 cutting-edge biomedical companies and delighting in witnessing their rapid growth.
Ren Bobing, Vice President of BV Investment, stated, “We believe that medical robots are not merely devices, but new business systems in the AI era. Although there are some large companies in certain directions, we believe that with high-granularity or multi-axis data perception, along with stronger computational and cognitive capabilities in the AI era, the device forms and business models of medical robots will undergo significant changes. We hope to identify innovative solutions with both imagination and technical strength through this competition, and more importantly, to find the teams behind these solutions who will transform the future of healthcare, accelerate the development of an entrepreneurial ecosystem for medical robotics, promote cross-disciplinary integration and resource aggregation in this emerging field, and provide support to entrepreneurs in this sector.”
VCBeat and VCBeat Research Institute have jointly released the "Special Report on Third-Party Sterile Supply Centers"
“Special Report on Third-Party Sterile Supply Centers” discusses the industry’s macro-environment, market demand, market supply, and case studies of representative enterprises. From the perspective of an independent observer, it aims to lift the veil over the industry and provide reference and insights for entrepreneurs in formulating strategies and for investors in making investment decisions.
China’s third-party sterile supply services started relatively late and are still in a growth phase. The national government has introduced relevant policies explicitly supporting the development of the third-party sterile supply services market, thereby creating a favorable macro-policy environment for enterprises. Coupled with the rising demand for outsourced hospital sterilization services, the market is now presented with significant opportunities for growth.
In terms of domestic demand for disinfection and sterilization, data published by the global growth consulting firm Frost & Sullivan shows that the market size of China’s third-party sterile supply centers achieved a compound annual growth rate (CAGR) of 70.2% over the past six years, rising from RMB 1.44 billion in 2013 to RMB 17.47 billion in 2018. This high CAGR is primarily attributable to the late start and low initial base of China’s third-party sterile supply centers, as well as the gradual liberalization of policies, which has spurred the development of third-party medical disinfection service enterprises.
Frost & Sullivan predicts that the market size of third-party sterile supply centers will continue to grow rapidly in the coming years, and is expected to reach 76 billion yuan by 2020. Under the opportunities and market demand, it will gradually undertake more than 70% of the sterilization and supply work of medical devices. This special report mainly focuses on the following core contents:
1. Policy Evolution Trajectory from 2009 to 2018
2. Construction Standards and Management and Operational Requirements
3. Market Landscape and Competitive Players
4. Comprehensive Comparison of Typical Business Models
5. How International Giants Such as STERIS Build Third-Party Sterile Supply Centers
At the event, Xu Jing, General Manager of Julikang, took the stage to deliver a speech as a key participant and promoter in the industry. Founded in 2010, Julikang is a leading third-party sterile supply service provider in China. It has established operations in seven cities, with eight operational centers currently serving over 200 hospitals. The company helps hospitals reduce operating costs of their sterile supply departments by 20–30%, maintains a 100% annual contract renewal rate, and has become the first third-party sterile supply center to achieve nationwide chain operations in China.
Julikang has established a comprehensive management and control system through six key pillars: standardized layout, specialized equipment, scientific training, quality control systems, intelligent processes, and end-to-end monitoring. This approach enhances operational efficiency, ensures the quality and safety of sterilization services, and builds a strong corporate brand.
Next Stop: Primary Care Theme Launch Day
Primary healthcare is the most fundamental and critical component of building an integrated healthcare system. Driven by policy support and technological innovation, the primary healthcare sector is undergoing continuous upgrading and transformation. This systemic change is leading to the deconstruction and reshaping of the industry, making primary healthcare inevitably the key entry point for patient flow in future healthcare delivery.
At this VB100 Primary Healthcare Theme Launch Day, we will bring together eight of the most watched listed companies, unicorns, and leading innovative enterprises in niche sectors within the primary healthcare industry—spanning internet hospitals, family physicians, private primary care providers, primary diagnostic testing, and new pharmaceutical marketing channels—to centrally announce major strategic updates, including new product launches, financing rounds, partnerships, reports, and plans. This concentrated release aims to create an information aggregation effect, thereby generating significant impact across the industry.
Meanwhile, the VB100 Primary Healthcare Theme Launch Day will invite dozens of media outlets from the medical and health, technology, venture capital, and finance sectors, alongside mainstream media, to attend in person. Through in-depth coverage and cross-platform synergy across the entire internet, we will jointly create a premier launch event for the primary healthcare industry.
VCBeat, a healthcare media outlet founded in 2014—the inaugural year of China’s internet healthcare era—has dedicated itself to covering the medical and health sector for the past five years. With profound industry insights and extensive industrial resources, VCBeat goes beyond the scope of traditional event management firms by helping enterprises devise comprehensive promotional strategies, thereby transforming corporate press conferences into “vibrant” hubs of communication momentum.
See details:Introduction to the Primary Care Themed Release Day